| 51. |
|
|
| 52. |
|
|
| 53. |
|
|
| 54. |
|
|
| 55. |
|
|
| 56. |
- Augustsson, J, et al.
(författare)
-
Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)
- 2010
-
Ingår i: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 69:1, s. 126-131
-
Tidskriftsartikel (refereegranskat)abstract
- To investigate the effect of tumour necrosis factor (TNF) antagonist treatment on workforce participation in patients with rheumatoid arthritis (RA).Methods:Data from the Stockholm anti-TNFα follow-up registry (STURE) were used in this observational study. Patients with RA (n = 594) aged 18–55 years, (mean (SD) 40 (9) years) followed for up to 5 years were included with hours worked/week as the main outcome measure. Analyses were performed unadjusted and adjusted for baseline age, disease duration, Health Assessment Questionnaire (HAQ), 28-joint Disease Activity Score (DAS28) and pain score.Results:At baseline patients worked a mean 20 h/week (SD 18). In unadjusted analyses, significant improvements in hours worked/week could already be observed in patients at 6 months (mean, 95% CI) +2.4 h (1.3 to 3.5), with further increases compared to baseline at 1-year (+4.0 h, 2.4 to 5.6) and 2-year follow-up (+6.3 h, 4.2 to 8.4). The trajectory appeared to stabilise at the 3-year (+6.3 h, 3.6 to 8.9), 4-year (+5.3 h, 2.3 to 8.4) and 5-year follow-up (+6.6 h, 3.3 to 10.0). In a mixed piecewise linear regression model, adjusted for age, sex, baseline disease activity, function and pain, an improvement of +4.2 h/week was estimated for the first year followed by an added improvement of +0.5 h/week annually during the years thereafter. Over 5 years of treatment, the expected indirect cost gain corresponded to 40% of the annual anti-TNF drug cost in patients continuing treatment.Conclusion:Data from this population-based registry indicate that biological therapy is associated with increases in workforce participation in a group typically expected to experience progressively deteriorating ability to work. This could result in significant indirect cost benefits to society.
|
|
| 57. |
|
|
| 58. |
|
|
| 59. |
|
|
| 60. |
|
|
| 61. |
|
|
| 62. |
|
|
| 63. |
|
|
| 64. |
|
|
| 65. |
|
|
| 66. |
- Bremberg, ER, et al.
(författare)
-
An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital
- 2006
-
Ingår i: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. - : SAGE Publications. - 1078-1552. ; 12:2, s. 75-81
-
Tidskriftsartikel (refereegranskat)abstract
- Aim. The aim of this project was to establish the importance of a pharmacist in the health-care team in improving drug use in an oncology ward in the Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. Methods and patients. The pharmacist participated in the medical round in the mornings and worked as a member of the health-care team. Drug-related problems (DRPs) were identified by drug chart reviews based on data from medical files, laboratory tests and interviews with patients and/or relatives. A questionnaire to physicians and nurses was used to evaluate their experiences of the pharmacist’s contribution to the oncology ward. Results. In total, 114 DRPs were identified in 58 patients. For each DRP, the pharmacist gave proposals for solutions. Sixty-eight suggestions out of 114 (59.6%) were implemented by the physician. Two suggestions (1.8%) were partly followed. For 32 suggestions (28.0%) it was unclear if they had caused any change in medication. Twelve suggestions (10.5%) were not followed. Most of the physicians and nurses acknowledged the pharmacist’s contribution to improved drug use in the ward. Conclusion. A pharmacist can improve drug use in an oncology ward as a member of the health-care team. The pharmacist contributes with a systematic focus on the patient from a drug perspective.
|
|
| 67. |
|
|
| 68. |
|
|
| 69. |
|
|
| 70. |
|
|
| 71. |
|
|
| 72. |
|
|
| 73. |
|
|
| 74. |
|
|
| 75. |
|
|
| 76. |
|
|
| 77. |
|
|
| 78. |
|
|
| 79. |
|
|
| 80. |
|
|
| 81. |
|
|
| 82. |
|
|
| 83. |
|
|
| 84. |
|
|
| 85. |
- Elfsson, B, et al.
(författare)
-
Stability of 5-aminolevulinic acid in aqueous solution
- 1999
-
Ingår i: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. - : Elsevier BV. - 0928-0987. ; 7:2, s. 87-91
-
Tidskriftsartikel (refereegranskat)
|
|
| 86. |
|
|
| 87. |
|
|
| 88. |
|
|
| 89. |
- Frost, Britt-Marie, et al.
(författare)
-
Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.
- 2002
-
Ingår i: Medical and pediatric oncology. - : Wiley. - 0098-1532 .- 1096-911X. ; 38, s. 329-
-
Tidskriftsartikel (refereegranskat)abstract
- In adults, it has been shown that the pharmacokinetics of doxorubicin are highly variable, despite standardization of the dose based on body surface area (BSA). The purpose of this study was to determine the plasma concentrations of doxorubicin and its active metabolite doxorubicinol in children treated for acute lymphoblastic leukemia (ALL).
|
|
| 90. |
- Fugelstad, A, et al.
(författare)
-
Use of morphine and 6-monoacetylmorphine in blood for the evaluation of possible risk factors for sudden death in 192 heroin users
- 2003
-
Ingår i: Addiction. - : Wiley. - 0965-2140 .- 1360-0443. ; 98:4, s. 463-470
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: To detect risk factors for sudden death from heroin injection. Design: Evaluation of data from forensic investigations of all fatal cases of suspected heroin death in a metropolitan area. Only cases with detectable morphine and 6-monoacetylmorphine (6-MAM) in blood were included in order to select heroin intoxication cases. Setting: Stockholm, Sweden. Measurements: Autopsy investigation and toxicological analysis of blood and urine: and police reports. Findings: In two-thirds of the 192 cases, death occurred in public places, and mostly without any time delay. Blood concentrations of morphine ranged from 50 to 1200 ng/g, and of 6-MAM from 1 to 80 ng/g. Codeine was detected in 96% of the subjects. In the majority of cases the forensic investigation indicated polydrug use, the most common additional findings being alcohol and benzodiazepines. However, in one-quarter of the cases other drug combinations were found. Previous abstinence from heroin and use of alcohol were identified as risk factors. For 6-MAM there was also a correlation with the presence of THC and benzodiazepines. Despite a high frequency of heart abnormalities (e.g. myocarditis and focal myocardial fibrosis), these conditions did not correlate with morphine or 6-MAM blood concentrations. Conclusions: We confirm that alcohol intake and loss of tolerance are risk factors for death from heroin use, whereas no connection to heart pathology was observed. Further, prospective, studies should focus on other possible risk factors.
|
|
| 91. |
|
|
| 92. |
|
|
| 93. |
|
|
| 94. |
|
|
| 95. |
|
|
| 96. |
|
|
| 97. |
|
|
| 98. |
|
|
| 99. |
|
|
| 100. |
|
|
